CompanyTrack
O

OXFORD ENDOVASCULAR LIMITED

Active Oxford

Research and experimental development on biotechnology

6 employees Website
Life sciences and medical technology Research and experimental development on biotechnology
O

OXFORD ENDOVASCULAR LIMITED

Research and experimental development on biotechnology

Founded 9 Sept 2015 Active Oxford, United Kingdom 6 employees oxfordendovascular.com
Life sciences and medical technology Research and experimental development on biotechnology
Accounts Submitted 3 Jul 2025
Confirmation Statement Submitted 1 Oct 2025
Net assets £7.67M £4.99M 2024 year on year
Total assets £0.00 £3.64M 2024 year on year
Total Liabilities £794.72K £161.42K 2024 year on year
Charges None No charges registered

AI Analysis

AI Analysis

Analyze director networks, ownership patterns, and company connections

CompanyTrack AI can make mistakes. Check important info.

Contact & Details

Registered Address

9400 Garsington Road Oxford Business Park Oxford OX4 2HN United Kingdom

Office (Oxford Science Park)

G4 Magdalen Centre, Robert Robinson Avenue, Oxford, OX4 4GA, United Kingdom

Credit Report

Discover OXFORD ENDOVASCULAR LIMITED's Credit Score, limit, and payment likelihood.

Mutual Companies

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type Total Exemption Full
Next accounts 31 December 2025
Due by 30 September 2026 9 months

Net Assets, Total Assets & Total Liabilities (2016–2024)

Cash in Bank

£7.92M

Increased by £5.12M (+183%)

Net Assets

£7.67M

Increased by £4.99M (+186%)

Total Liabilities

£794.72k

Decreased by £161.42k (-17%)

Turnover

N/A

Employees

6

Decreased by 1 (-14%)

Debt Ratio

N/A

Decreased by 26 (-100%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
Dec Year End
2023
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

£350k awarded
Show:

Investors (0)

No investor information available

Share Capital

Share Capital

Share allotments and capital structure

12 Allotments 383,526 Shares £15.68m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
2 Jan 20256,000£60£0.01
25 Apr 20243,232£133k£41.16
11 Apr 2024243£10k£41.16
9 Apr 202446,888£1.93m£41.16
3 Apr 20247,701£360k£46.77

Officers

Officers

6 active 6 resigned
Status
Charles Richard TaylorDirectorBritishUnited Kingdom671 Jan 2020Active
James Vincent ByrneDirectorBritishEngland7523 Dec 2015Active
Martin Henry DiggleDirectorBritishSouth Africa6319 Feb 2021Active
Parkwalk Advisors LtdCorporate-directorUnited KingdomUnknown24 Apr 2019Active
Pennsec LimitedCorporate-secretaryUnited KingdomUnknown20 Sept 2017Active
Xie FengDirectorChineseChina4123 Dec 2015Active

Shareholders

Shareholders (26)

Zhaoxuan Chen
4.3%
32,0911 Oct 2025
Zhong You
2.7%
20,2001 Oct 2025
Yavuz Ahiska
0.4%
3,1291 Oct 2025

Persons with Significant Control

Persons with Significant Control (1)

1 Active 2 Ceased

Parkwalk Advisors Ltd

United Kingdom

Active
Notified 9 Apr 2024
Nature of Control
  • Voting Rights 25 To 50 Percent

Oxford Sciences Innovation Plc

Ceased 30 Mar 2021

Ceased

Parkwalk Advisors Ltd

Ceased 8 Feb 2024

Ceased

Group Structure

Group Structure

PARKWALK ADVISORS LTD united kingdom shares 75 to 100 percent
IP GROUP PLC united kingdom
OXFORD ENDOVASCULAR LIMITED Current Company

Charges

Charges

No charges registered

Documents

Company Filings

DateCategoryDescriptionDocument
1 Oct 2025Confirmation StatementConfirmation statement made on 2025-09-09 with updatesView(6 pages)
3 Jul 2025AccountsAnnual accounts made up to 2024-09-30View(13 pages)
6 Jan 2025CapitalAllotment of shares (GBP 7,444.53) on 2025-01-02View(3 pages)
4 Oct 2024OfficersTermination of Michael Karim as director on 2024-09-30View(1 page)
16 Sept 2024OfficersChange to director Professor James Vincent Byrne on 2015-12-23View(2 pages)
1 Oct 2025 Confirmation Statement

Confirmation statement made on 2025-09-09 with updates

3 Jul 2025 Accounts

Annual accounts made up to 2024-09-30

6 Jan 2025 Capital

Allotment of shares (GBP 7,444.53) on 2025-01-02

4 Oct 2024 Officers

Termination of Michael Karim as director on 2024-09-30

16 Sept 2024 Officers

Change to director Professor James Vincent Byrne on 2015-12-23

Recent Activity

Latest Activity

Confirmation statement made on 2025-09-09 with updates

4 months ago on 1 Oct 2025

Annual accounts made up to 2024-09-30

7 months ago on 3 Jul 2025

Allotment of shares (GBP 7,444.53) on 2025-01-02

1 years ago on 6 Jan 2025

Termination of Michael Karim as director on 2024-09-30

1 years ago on 4 Oct 2024

Change to director Professor James Vincent Byrne on 2015-12-23

1 years ago on 16 Sept 2024